Literature DB >> 2403595

Hemorrhagic cystitis: a review.

C R deVries1, F S Freiha.   

Abstract

Acute, fulminant bladder hemorrhage usually is seen at tertiary care centers in which cancer patients are treated with oxazaphosphorine alkylating agents, particularly cyclophosphamide and isophosphamide. These agents also are used to treat benign conditions, such as lupus erythematosis and Wegener's granulomatosis. Radiation effects from treatment of prostatic or cervical carcinoma can appear for the first time as late as 15 to 20 years after initial treatment. Other iatrogenic causes of bleeding include treatment with penicillins and, rarely, danazol. Occasionally, bladder hemorrhage may be the presenting sign of metabolic disease, such as secondary amyloidosis in rheumatic arthritis. Cases of mild to moderate hemorrhagic cystitis arising in the otherwise healthy patients should lead one to pursue the possibility of environmental toxins, accidental poisoning, recreational drug use or viruses. In all cases the diagnosis should be reserved until more common causes of hematuria, such as bacterial or fungal infection, stones, cysts or tumors, have been ruled out. Prevention of chemotherapeutically induced cystitis ideally will follow careful attention to adequate hydration and the prophylactic use of antitoxins, such as mesna. Treatment, as outlined previously, consists of a series of measures beginning with the most conservative. Intervention thereby is tailored to the gravity of the clinical situation.

Entities:  

Mesh:

Year:  1990        PMID: 2403595     DOI: 10.1016/s0022-5347(17)39848-8

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  23 in total

1.  Novel treatment strategy for refractory hemorrhagic cystitis following radiation treatment of genitourinary cancer: Use of 980-nm diode laser.

Authors:  Dharam Kaushik; Benjamin A Teply; George P Hemstreet
Journal:  Lasers Med Sci       Date:  2012-02-28       Impact factor: 3.161

2.  Superselective vesical artery embolization in the management of intractable hematuria secondary to hemorrhagic cystitis.

Authors:  Suyash Mohan; Sunil Kumar; Deepak Dubey; Rajendra V Phadke; Sanjay S Baijal; Manoj Kathuria
Journal:  World J Urol       Date:  2018-12-17       Impact factor: 4.226

Review 3.  Cyclophosphamide toxicity. Characterising and avoiding the problem.

Authors:  L H Fraiser; S Kanekal; J P Kehrer
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

Review 4.  Optimisation of cyclophosphamide therapy in systemic vasculitis.

Authors:  R Richmond; T W McMillan; R A Luqmani
Journal:  Clin Pharmacokinet       Date:  1998-01       Impact factor: 6.447

Review 5.  Evidence-Based Practice Recommendations for Hydration in Children and Adolescents With Cancer Receiving Intravenous Cyclophosphamide.

Authors:  Deborah Robinson; Ginny Schulz; Rachel Langley; Kevin Donze; Kari Winchester; Cheryl Rodgers
Journal:  J Pediatr Oncol Nurs       Date:  2014-05-05       Impact factor: 1.636

Review 6.  Management of radiation cystitis.

Authors:  Shaun G Smit; Chris F Heyns
Journal:  Nat Rev Urol       Date:  2010-03-09       Impact factor: 14.432

7.  Endogenous nerve growth factor regulates collagen expression and bladder hypertrophy through Akt and MAPK pathways during cystitis.

Authors:  Chul-Won Chung; Qing L Zhang; Li-Ya Qiao
Journal:  J Biol Chem       Date:  2009-12-07       Impact factor: 5.157

8.  Rupture of the urinary bladder following cystoscopic clot evacuation: report of two cases diagnosed by CT.

Authors:  D P Smith; S M Goldman; E K Fishman
Journal:  Abdom Imaging       Date:  1994 Mar-Apr

9.  Hemorrhagic cystitis: A challenge to the urologist.

Authors:  R Manikandan; Santosh Kumar; Lalgudi N Dorairajan
Journal:  Indian J Urol       Date:  2010-04

Review 10.  Prevention and management of the adverse effects associated with immunosuppressive therapy.

Authors:  S J Rossi; T J Schroeder; S Hariharan; M R First
Journal:  Drug Saf       Date:  1993-08       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.